Publication details

Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

Authors

ANTUNES Liliana MAZAGATOS Clara MARTÍNEZ-BAZ Iván GOMEZ Verónica MARIA-LOUISE Borg PETROVIĆ Goranka DUFFY Róisín DUFRASNE François E DÜRRWALD Ralf LAZAR Mihaela JANCORIENE Ligita OROSZI Beatrix HUSA Petr HOWARD Jennifer MELO Aryse POZO Francisco PÉREZ-GIMENO Gloria CASTILLA Jesús MACHADO Ausenda DŽIUGYTE Aušra KARABUVA Svjetlana FITZGERALD Margaret FIERENS Sébastien TOLKSDORF Kristin SILVIA-ODETTE Popovici MICKIENE Aukse TÚRI Gergő SOUČKOVÁ Lenka NICOLAY Nathalie ROSE Angela Mc

Year of publication 2024
Type Article in Periodical
Magazine / Source EUROSURVEILLANCE
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708#abstract_content
Doi http://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708
Keywords bivalent mRNA COVID-19 vaccines;Omicron XBB lineage-predominant period;VEBIS SARI VE network
Description We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged???60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated >?6 months before the campaign: from 80% (95%?CI: 50?to?94) for 14–89 days post-vaccination, 15% (95%?CI: -12?to?35) at 90–179 days, and lower to no effect thereafter.

You are running an old browser version. We recommend updating your browser to its latest version.

More info